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Abstract
Effective vaccination is now available to prevent human papillomavirus (HPV), the most common 
sexually transmitted infection and cause of cervical cancer. This study aimed to estimate the 
prevalence of HPV vaccination among childhood cancer survivors and identify factors associated 
with HPV vaccine initiation and completion. Mothers of daughters aged 9–17 years with/without a 
history of childhood cancer (n = 235, Mage= 13.2 years, SD= 2.69; n = 70, Mage= 13.3 years, 
SD=2.47, respectively) completed surveys querying HPV vaccination initiation and completion 
along with socio-demographic, medical, HPV knowledge and communication, and health belief 
factors, which may relate to vaccination outcomes. Multivariate logistic regression was utilized to 
identify factors which associate with HPV vaccination initiation and completion. Among cancer 
survivors, 32.6% initiated and 17.9% completed the 3-dose vaccine series, whereas 34.3% and 
20.0% of controls initiated and completed, respectively. Univariate analyses indicated no 
differences between cancer/no cancer groups on considered risk factors. Among all participants, 
multivariate logistic regression analyses found vaccine initiation associated with older age of 
daughter and physician recommendation, while increased perceived barriers associated with a 
decreased likelihood of initiation (all Ps < .05). Among those having initiated, risk factors for non-
completion included being non-white, increased perceived severity of HPV, and increased 
perceived barriers to vaccination (all Ps < .05). A minority of adolescents surviving childhood 
cancer have completed vaccination despite their increased risk for HPV-related complication. 
These results inform the prioritization of strategies to be included in vaccine promotion efforts.
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INTRODUCTION
Genital human papillomavirus (HPV) is the most common sexually transmitted infection (1) 
and has a causal role in the expression of cervical and other cancers (2). Approximately 80% 
of sexually active women are exposed to HPV during their lifetime (3), and HPV is most 
prevalent among females aged 20–24 years (4). Rates rise sharply after the median age of 
sexual debut, 16.6 years for females in the US (5). Recent efforts to reduce cervical cancer 
have led to the development of vaccines to protect against HPV, which are currently 
available and have been demonstrated to be safe and effective (6–10). Quadrivalent HPV 
vaccination, approved in 2006 for females between 9–26 years of age (11) protects against 
HPV types 16 and 18 (which account for 70% of cervical cancers) and 6 and 11 (which 
account for 90% of genital warts) (12). In 2009, HPV vaccination was also approved for 
males (13).
Routine HPV vaccination is currently recommended by the Advisory Committee on 
Immunization Practices for adolescent girls aged 11 and 12 years, with catch-up vaccination 
for women up to age 26 (14). It is recommended that the vaccine be administered prior to 
sexual debut due to the mechanism of HPV transmission (11). With appropriate utilization 
of the vaccine, the American Cancer Society estimates a potential reduction of cervical 
cancer risk by over 70% over the next decade (15–16). HPV vaccine uptake is particularly 
important for females surviving childhood cancer, many of whom are at increased risk for 
HPV-related complications secondary to the direct and indirect effects of cancer treatment. 
Survivors at increased risk for HPV persistence and complications include those with a 
history of hematopoietic stem cell transplantation (17), Hodgkin lymphoma (18–19), 
treatment with pelvic irradiation (20–21), and those receiving other cancer treatments 
resulting in sustained immunosuppression (22–26). Survivors of childhood cancer appear to 
also be at increased risk for HPV infection/complication/escalation given the unique 
behavioral, cognitive, and educational consequences of treatment. Specifically, survivors of 
childhood cancer are less likely than their healthy siblings to have undergone a Papanicolaou 
(Pap) smear within the previous three years (27). Survivors are also more likely to 
experience neurocognitive deficits such as impulsivity and inattention resembling attention 
deficit hyperactivity disorder, which have been associated with increased risky and sexual 
behaviors (28–32). Additionally, survivors of childhood cancer are more likely to report 
unemployment, lower educational attainment, and lower annual incomes (33), factors 
independently associated with HPV infection. As such, the Children’s Oncology Group’s 
(COG) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and 
Young Adult Cancer Version 3.0, which is the template for screening late effects of cancer 
treatment, has recommended HPV vaccination for all eligible females surviving childhood 
cancer (34).
Over the last two years, the National Immunization Survey for Teens (utilizing clinic 
validated repots) found that initiation rates among adolescent females in the general 
population ranged from 48.7% to 53.0% whereas completion rates have ranged from 32.0% 
to 34.8% (35–36). Both rates of initiation and completion are significantly lower than the 
80% target established by the Healthy People 2020 initiative (37). Because the HPV vaccine 
was only approved recently by the FDA (2006), little is known about the complexity of 
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vaccination uptake among those surviving cancer. To date, no rigorous examination of HPV 
vaccination among survivors of childhood cancer has been reported. The current study 
serves as the first prevalence estimation of HPV vaccination initiation and completion 
among a large cohort of childhood cancer survivors while also identifying factors which are 
most influential in HPV vaccination initiation and completion in this high-risk group.
MATERIALS AND METHODS
Participants
Maternal caregivers who have daughters with a history of childhood cancer were recruited 
from the After Completion of Therapy (ACT) Clinic at St. Jude Children’s Research 
Hospital. ACT is a long-term follow-up clinic for childhood cancer survivors who are 
greater than 5 years post-diagnosis, and 2 years disease-free. Following completion of the 
study questionnaire, each mother was asked to provide contact information for up to 5 
acquaintances in order to obtain a control sample demographically similar to the cancer 
group. This type of sampling allowed for the evaluation of HPV vaccination rates across 
cancer/no cancer groups while controlling for key demographic variables (daughter’s age, 
socioeconomic status, maternal education, and region of the country), which have been 
found to influence vaccination uptake (36,38–41). By controlling for these specific 
demographics, the distinguishing feature between groups was the presence/absence of 
daughter cancer history. Eligibility criteria for participants included: 1) the mother or female 
primary caregiver of a female 9–17 years of age, 2) proficient in reading and writing 
English, 3) cognitively able to understand and complete the study questionnaire, and 4) 
willing and able to provide informed consent per institutional review board (IRB) 
guidelines. Over an 18-month interval, a total of 235 mothers with daughters with a history 
of childhood cancer (“cancer survivor” group; daughter Mage = 13.2 years, SD = 2.69) and 
70 mothers with daughters without cancer (“acquaintance control;” daughter Mage = 13.3 
years, SD = 2.47) were enrolled in the study and returned questionnaires (Figure 1). Cancer 
survivors and acquaintance controls did not significantly differ on any of the measured 
demographic variables (Table 1).
Among the cancer survivor group, maternal caregivers were recruited during their 
daughter’s regularly scheduled ACT Clinic visit. A trained member of the research team 
approached mothers, explained the purpose of the study, and obtained informed consent as 
approved by the IRB. After consent was obtained, participants completed paper-and-pencil 
questionnaires, which took approximately 15–30 minutes. Potential acquaintance control 
participants were contacted via telephone based on contact information provided by the 
mothers with daughters with a cancer history (typically by accessing information stored on 
their cellular phones). Controls who verbally consented via telephone were provided the 
option of completing either an online questionnaire or a mailed paper-and-pencil 
questionnaire. Questionnaires were identical across the two groups, aside from identifying 
the St. Jude daughters as “patients.” After completing questionnaires, all participants were 
provided with an information sheet on HPV and HPV vaccination. Questionnaires were 
collected in 2010 and 2011.
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Outcome Variables—HPV vaccine initiation/non-initiation was defined as a binary 
outcome variable such that mothers who reported their daughters have received one or more 
HPV vaccine doses were categorized as “initiated,” and those having received zero doses 
were categorized as “non-initiated.” HPV vaccine completion/non-completion was defined 
as a binary outcome variable such that mothers who reported their daughters have received 
all three doses of HPV vaccine were categorized as complete, and those who have received 
at least one dose but less than three doses of HPV vaccine were categorized as incomplete. 
Participants whose daughters have received zero doses of the HPV vaccine were excluded in 
the modeling of HPV vaccination completion.
Independent Variables—All participants completed questionnaires regarding their 
daughters’ socio-demographic and medical history, HPV-specific knowledge and 
communication, and health beliefs.
Medical and Socio-Demographic Variables
Mothers provided familial demographic information, including maternal and child age, race/
ethnicity, marital status, education level, and annual household income, along with medical 
history of gynecological care and cervical cancer screening. Items were adapted from 
instruments previously used in the HPV vaccine literature (42–44) (Table 1). Items 
measuring maternal perceptions of daughter’s sexual activity and relationship status were 
also adapted from previous self-report questionnaires (41).
HPV Knowledge and Communication
Knowledge of HPV, cervical cancer, and HPV vaccination was measured by a scale adapted 
from Brabin and colleagues (42). Correct responses to 10 multiple choice items were 
summed for a total knowledge score, with higher scores representing greater knowledge. 
The questionnaire content was abstracted from the CDC’s HPV vaccination information 
website as well as other sources (42,45). Familial communication regarding the messages 
and purpose of HPV vaccination was assessed via a 4-item scale also adapted from Brabin 
and colleagues (42). The 18 item Mother-Adolescent Sexual Communication Instrument 
assessed maternal-adolescent sexual behavior and development communication (46). 
Internal reliability in our sample was high (α =.92) and convergent and discriminant validity 
have been previously established and described (46). Communication scores were recoded 
into binary variables (median splits) prior to model inclusion: HPV communication (Mdn = 
14, Range = 4–16), and sexual communication (Mdn = 68, Range = 18–90).
Health Beliefs
The HPV Vaccine Health Beliefs Questionnaire (47) is a validated instrument designed to 
measure maternal perceptions of daughters’ vulnerability to HPV, severity of HPV, barriers 
to, benefits of, and self-efficacy for initiating/completing the vaccine. Internal reliability was 
acceptable for all subscales in our sample: Vulnerability (α = .95), Severity (α = .87), 
Barriers (α = .81), Benefits (α = .82), and Self-Efficacy (α = .91). Cox and colleagues (47) 
also found the internal reliabilities of these factors to be robust which contributed to 
establishing the predictive validity of health belief factors as it relates to HPV vaccination 
acceptability among mothers of girls aged 11–16 years. Additional measures of vaccine-
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related Cues to Action and Social Environmental Influence were also considered with scales 
adapted from previously validated surveys (42–44,47). Health belief scores were recoded 
into binary variables (median splits) prior to model inclusion: Vulnerability (Mdn = 12.0, 
Range = 5–25), severity (Mdn = 32, Range = 8–40), barriers (Mdn = 25, Range = 12–52), 
benefits (Mdn = 23, Range = 8–35), and self-efficacy (Mdn = 24, Range = 6–30).
Statistical Analysis
Univariate analyses were utilized to examine differences between groups (cancer history/no 
history) in HPV vaccine initiation and completion. Univariate differences were also assessed 
as a function of socio-demographic, medical, knowledge and communication, as well as 
health belief factors. Comparisons with p-values less than .10 were included in each of the 
two multivariate models (vaccine initiation and completion). Differences for continuous 
variables were assessed using univariate one-way analysis of variance (ANOVA). 
Differences in categorical variables were assessed using Chi-square and Fisher’s Exact tests. 
Multivariable logistic regression models were used to calculate odds ratios (OR) and 95% 
confidence intervals (CI) for vaccine outcomes. Given that no differences emerged between 
groups on vaccination outcomes, cancer survivors and acquaintance control participants 
were combined in the presented multivariate models. Participant status (cancer vs. control) 
was also retained as a factor in both models.
RESULTS
Univariate Cancer/Control Comparisons
Univariate differences emerged between cancer/no cancer groups on risk factors including 
vulnerability to HPV infection and complication (P = .04) and prediction of daughter’s 
sexual activity (P = .09). Specifically, mothers of daughters with a cancer history perceived 
their child to be more susceptible to HPV infection and complication, but were less likely to 
predict that their daughters would be sexually active by high school graduation. No other 
significant cancer/control differences were found on any other socio-demographic and 
medical history variables, HPV-specific knowledge and communication variables, or health 
belief variables.
Prevalence
Overall, 32.6% (75/230) of cancer survivors and 34.3% (24/70) healthy controls had 
initiated the HPV vaccine series. Among those who had initiated, 56.0% (42/75) of cancer 
survivors and 58.3% (14/24) of healthy controls had completed the vaccine series. In the 
overall sample, 17.9% (42/230) of survivors and 20% (14/70) of controls had completed the 
vaccine. No significant differences emerged in the rates of vaccine initiation or completion 
between cancer survivors and healthy controls.
HPV Vaccine Initiation
Univariate analyses revealed significant differences between those who have/have not 
initiated the HPV vaccine (see Tables 2 and 3). Based on the univariate findings, the 
multivariate model for HPV vaccine initiation included the following variables: race, 
daughter’s age, adolescent history of gynecological care, adolescent history of annual Pap 
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smear, doctor recommendation for vaccine, parental permission to date socially, maternal 
perception of daughter’s past and current relationship status, maternal perception of 
daughter’s sexual activity status, maternal-adolescent sexual communication, and maternal 
health beliefs of vulnerability, barriers to vaccination, benefits of vaccinating, and self-
efficacy regarding HPV vaccination (Table 4). The final multivariate logistic regression 
model predicting binary vaccine initiation outcome indicated that older daughter age and 
physician recommendation for vaccination were associated with an increased likelihood of 
HPV vaccine initiation. Furthermore, mothers who perceived greater barriers to having their 
daughter receive the HPV vaccine (e.g., financial or religious conflicts, concerns about 
vaccine promoting sexual activity in daughter, historical lack of vaccination endorsement, 
etc.) were less likely to have initiated the vaccine.
HPV Vaccine Completion
Univariate analyses for participants who had initiated the vaccine revealed significant 
differences between those who have/have not completed the vaccine series (Tables 2 and 3). 
Based on these differences, the final multivariate logistic regression model for HPV vaccine 
completion included the following variables: Race, daughter’s age, physician 
recommendation for HPV vaccination, parental permission for dating socially, and maternal 
health beliefs of vulnerability, severity, and barriers regarding HPV vaccination (Table 5). 
Among vaccine-initiated participants, those who were non-white, held perceptions of greater 
HPV severity, and who perceived greater barriers to vaccination were less likely to have 
completed the HPV vaccine series post initiation.
DISCUSSION
Advances in the treatment of childhood cancer have resulted in the majority of survivors 
living into adulthood (48–49). Given the reduction of mortality associated with cancer 
treatment, increased attention has been placed on promoting health and quality of life in 
survivorship (29, 50). HPV vaccination is one tool to assist in these efforts, and as such, a 
need exists to better understand vaccine prevalence and determinants in this vulnerable 
group.
Based on maternal report, the results of our study found that 32.6% of cancer survivors have 
initiated the vaccine series, whereas 17.9% have completed it. No differences in vaccine 
rates were identified between cancer survivors and acquaintance control groups, but 
univariate differences in known risk factors for vaccine initiation and completion did 
emerge. Specifically, mothers of survivors perceived greater vulnerability to HPV-related 
complication upon patient exposure but were less likely to believe that their daughters would 
engage in sexual activity prior to high school graduation. Although survivors are at 
increased risk for HPV-related complication, they did not engage in higher rates of 
vaccination. Cancer survivors and control participants were similar on many risk factors 
previously identified as being predictive of vaccination status, including age (39) physician 
recommendation (51–54) and race (36,38,55). The similarities between groups are consistent 
with previous research which identified no differences in risky sexual behavior between 
adolescent childhood cancer survivors and healthy siblings (56). Conceivably, interventions 
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designed to increase vaccine uptake in the healthy population may be generalizable for 
utilization among childhood cancer survivor populations as well based on these similarities.
Among the entire sample, the modeling of determinants associated with vaccine initiation 
found that older daughter age and physician recommendation were both related to increased 
vaccine uptake, whereas perceptions of high vaccine barriers were associated with decreased 
initiation. Our study aligns with previous research demonstrating that physician 
recommendation for HPV immunization is a robust predictor of vaccine uptake (52,57). It is 
interesting to note that only half of all mothers endorsed physician recommendation for HPV 
vaccination. Amidst the non-significant cancer/control differences described in the results, a 
trend was seen in which a minority of survivor families received a physician 
recommendation for vaccination, whereas a majority of controls reported receiving one. This 
is discouraging given survivors’ frequency of medical encounters and their increased risk for 
HPV-related complication (58). These data suggest potential confusion in vaccine 
management in that some primary care physicians may assume that oncologists are 
managing this aspect of care and vice versa. This lack of clarity may account for these less 
than optimal vaccine rates in the cancer group, and physician communication/
recommendation may be targets of future intervention, particularly in light of physician 
recommendation being predictive of vaccine initiation. Physician endorsement of HPV 
vaccination, as well as problem-solving specific to perceived barriers to vaccine initiation or 
completion, may also be mechanisms to increase vaccine uptake in adolescents (59).
Once the vaccine has been initiated, the series must be completed to achieve maximum 
protection (6). Being non-white and perceiving high barriers and severity associated with 
HPV infection/complication are all risk factors decreasing the likelihood of vaccine 
completion. The interpretation of the finding regarding high perceptions of HPV severity 
and its association with non-completion, while unexpected, is primarily a function/limitation 
of the cross sectional study design. It appears that mothers whose daughters have completed 
the vaccine series are least concerned about the severity of future HPV complications. This 
is presumably due to the comfort associated with full vaccine protection. This also suggests 
that an awareness of HPV-related complications could act as a motivator for vaccine 
completion. Modifiable variables consistent with the Health Belief Model (60) such as 
perceived severity and barriers to vaccination (and to a lesser extent vulnerability to HPV 
infection), should be prioritized in vaccine promotion efforts. Furthermore, there may be 
other modifiable variables which, though significant at the univariate level, did not reach 
significance in the multivariate models. Given the opportunity, interventionists may consider 
targeting such variables, like HPV communication or health beliefs, as part of vaccine 
promotion efforts in the future.
This is the first study to report the prevalence and correlates of HPV vaccination in 
childhood cancer survivors; however, this work was limited by a) inclusion of females from 
a single-site, b) survivors greater than 5 years post diagnosis, and c) utilized maternal report 
of child vaccination only. Furthermore, with cross-sectional study designs, only associations 
(not causalities) can be determined between the considered risk factors and vaccine 
outcomes. This literature is in the early stages of quantifying HPV-specific risk profiles 
among survivors of childhood cancer (61), necessitating additional research in this 
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population. Additionally, our definition of incompletion did not differentiate pending versus 
intentionally incomplete participants. It is possible that our incomplete group is 
heterogeneous in their intentions to complete the vaccine series. Related to this point, 
although all adolescents in the study were within the age indication for receiving the 
vaccine, the time since vaccine initiation and questionnaire completion may have been less 
than 6 months. As such, it is possible that the reported rates of vaccine completion in this 
sample may vary as a function of time since vaccination initiation.
Despite the COG recommendation for vaccination, the immunogenicity of the HPV vaccine 
among childhood cancer survivors has not yet been demonstrated. Among children living 
with HIV, for example, differences have been noted in quadrivalent HPV vaccine 
seroconversion, as titers against HPV subtypes 6 and 18 were demonstrated to be 30–50% 
lower than age matched controls (62). In response, a Phase II study is warranted examining 
the safety, immunogenicity, and tolerability (as well as scheduling and dosing of vaccine) 
among survivors of childhood cancer. In addition, future research should examine cancer-
specific factors (e.g. diagnosis, treatment, etiology) and their associations with HPV vaccine 
outcomes among survivors. As the HPV vaccine is also approved for young adults and 
males, examining factors contributing to vaccinations in these groups are warranted as well.
In conclusion, cancer survivors are at increased risk for adverse late effects including second 
malignancies and organ compromise, and as such, would benefit from HPV vaccination. 
Findings of the current study establish the prevalence and identification of factors 
influencing HPV vaccination among adolescent females surviving childhood cancer and 
their peers. A minority of adolescents surviving childhood cancer have initiated or 
completed HPV vaccination despite their increased risk for HPV complication. Future 
interventions designed to increase vaccination among childhood cancer survivors may draw 
upon these study findings to enhance immunization rates and promote their daughters’ 
health in the future.
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Figure 1. 
Flowchart depicting recruitment and questionnaire completion for mothers of cancer 
survivors and mothers of controls
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Table 1
Demographic and Treatment Characteristics of Study Participants*
Maternal Caregiver
Cancer Survivors n = 230 Controls n = 70 Combined N = 300
Freq (%) Freq (%) Freq (%)
Race/Ethnicity
 White 175 (76.1) 54 (77.1) 229 (76.3)
 Non-White 55 (23.9) 16 (22.9) 71 (23.7)
Marital Status
 Married 159 (69.1) 54 (77.1) 213 (71.0)
 Divorced/Separated/Widowed 39 (17.0) 12 (17.1) 51 (17.0)
 Other 29 (12.6) 4 (5.7) 33 (11.0)
 Missing 3 (1.3) 0 (0) 3 (1.0)
Education Level
 Less than College Degree 152 (65.1) 44 (62.9) 196 (65.3)
 College Degree or more 72 (31.3) 26 (37.1) 98 (32.7)
 Missing 6 (2.6) 0 (0) 6 (2.0)
Household Income
 Less than $20,000 37 (16.1) 5 (7.1) 42 (14.0)
 $20,000 to $59,999 74 (32.2) 24 (34.3) 98 (32.7)
 $60,000 and above 108 (47.0) 36 (51.4) 144 (48.0)
 Missing 11 (4.8) 5 (7.1) 16 (5.3)
Age (in Years)
 18–40† 107 (46.5) 31 (44.3) 138 (46.0)
 41–62 123 (53.5) 39 (55.7) 162 (54.0)
Age of Daughter (in Years)
 9–13 113 (49.1) 38 (54.3) 151 (50.3)
 14–17 117 (50.9) 32 (45.7) 149 (49.7)
Daughter’s Cancer Diagnosis
 Leukemia/Lymphoma 88 (38.3) -- --
 Brain/CNS Tumor 44 (19.1) -- --
 Solid Tumor 98 (42.6) -- --
Time from Diagnosis (in Years)
 5–7 53 (23.0) -- --
 8–11 117 (50.9) -- --
 12–15 48 (20.9) -- --
 16–19 12 (5.2) -- --
Age at Diagnosis (in Years)
 0–4 173 (75.2) -- --
 5–8 48 (20.9) -- --
 9–12 9 (3.9) -- --
*Note: There were no cancer/control group differences among variables presented in Table 1.
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†One self-identified “maternal caregiver” in this group was an older sister 18 years of age. The next youngest mother was 27 years of age.
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Table 2
Univariate Analysis for Socio-demographic and Medical Factors by HPV Vaccination Status
Not Initiated n = 201‡ Initiated n = 99 Incomplete† n = 43 Complete n = 56
Freq (%) Freq (%) Freq (%) Freq (%)
Health Status
 Cancer Survivor 155 (67.4) 75 (32.6) 33 (44) 42 (56)
 Healthy Control 46 (65.7) 24 (34.3) 10 (41.7) 14 (58.3)
Race of Maternal Caregiver
 White 160 (69.9) 69 (30.1) * 25 (36.2) 44 (63.8) **
 Non-White 41 (57.7) 30 (42.3) 18 (60) 12 (40)
Age of Daughter (in Years)
 9–13 123 (81.5) 28 (18.5) *** 15 (53.6) 13 (46.4) **
 14–17 78 (52.3) 71 (47.7) 28 (39.4) 43 (60.6)
Daughter Sees OB/GYN
 No 173 (72.7) 65 (27.3) *** 28 (43.1) 37 (56.9)
 Yes 24 (45.3) 29 (54.7) 12 (41.4) 17 (58.6)
Daughter Gets Yearly Pap Test
 No 185 (70.9) 76 (29.1) *** 32 (42.1) 44 (57.9)
 Yes 10 (37.0) 17 (63) 7 (41.2) 10 (58.8)
Doctor Recommended Vaccine
 No 126 (88.7) 16 (11.3) *** 10 (62.5) 6 (37.5) *
 Yes 64 (45.1) 78 (54.9) 30 (38.5) 48 (61.5)
Allowed to Date
 No 151 (76.6) 46 (23.4) *** 24 (52.2) 22 (47.8) *
 Yes 39 (45.3) 47 (54.7) 16 (34) 31 (66)
Current Relationship
 No 174 (70.4) 73 (29.6) ** 34 (46.6) 39 (53.4)
 Yes 23 (52.3) 21 (47.7) 6 (28.6) 15 (71.4)
Past Relationship
 No 172 (72.6) 65 (27.4) *** 30 (46.2) 35 (53.8)
 Yes 18 (40) 27 (60) 11 (40.7) 16 (59.3)
Sexually Active, Current
 No 185 (68.8) 84 (31.2) * 37 (44) 47 (56)
 Yes 7 (46.7) 8 (53.3) 3 (37.5) 5 (62.5)
Sexually Active, Past
 No 179 (69.6) 78 (30.4) *** 35 (44.9) 43 (55.1)
 Yes 10 (38.5) 16 (61.5) 5 (31.3) 11 (68.8)
Predict Sexual Activity by H.S. Grad
 No 121 (70.3) 51 (29.7) ** 20 (39.2) 31 (60.8)
 Yes 27 (50.9) 26 (49.1) 12 (46.2) 14 (53.8)
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Not Initiated n = 201‡ Initiated n = 99 Incomplete† n = 43 Complete n = 56
Freq (%) Freq (%) Freq (%) Freq (%)
 Not Sure 45 (72.6) 17 (27.4) 9 (52.9) 8 (47.1)
***
p<.01;
**
p<.05;
*
p<.10; These p-values are associated with Chi-square tests which examined group differences on the variables.
†
Percent based on number having received at least one dose of HPV vaccine.
‡All n’s may not equal 300 or 99 due to missing data.
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Table 3
Univariate Analysis for Communication and Health Belief Factors by HPV Vaccination Status
Not Initiated n = 201‡ Initiated n = 99 Incomplete† n = 43 Complete n = 56
Freq (%) Freq (%) Freq (%) Freq (%)
Maternal-Adolescent Communication
 Low 105 (80.2) 26 (19.8) *** 9 (34.6) 17 (65.4)
 High 80 (55.6) 64 (44.4) 29 (45.3) 35 (54.7)
HPV Communication
 Low 89 (76.7) 27 (23.3) *** 9 (33.3) 18 (66.7)
 High 87 (58.4) 62 (41.6) 28 (45.2) 34 (54.8)
Health Belief Factor: Vulnerability
 Low 87 (57.6) 64 (42.4) *** 24 (37.5) 40 (62.5) *
 High 105 (79.5) 27 (20.5) 14 (51.9) 13 (48.1)
Health Belief Factor: Severity
 Low 85 (63.9) 48 (36.1) 16 (33.3) 32 (66.7) **
 High 110 (70.5) 46 (29.5) 23 (50.0) 23 (50.0)
Health Belief Factor: Barriers
 Low 75 (53.6) 65 (46.4) *** 22 (33.8) 43 (66.2) *
 High 120 (82.8) 25 (17.2) 17 (68.0) 8 (32.0)
Health Belief Factor: Benefits
 Low 105 (80.8) 25 (19.2) *** 12 (48.0) 13 (52.0)
 High 89 (56.0) 70 (44) 29 (41.4) 41 (58.6)
Health Belief Factor: Self-Efficacy
 Low 110 (74.8) 37 (25.2) *** 16 (43.2) 21 (56.8)
 High 86 (60.1) 57 (39.9) 25 (43.9) 32 (56.1)
***
p<.01;
**
p<.05;
*
p<.10; These p-values are associated with Chi-square tests which examined group differences on the variables.
†
Percent based on number having received at least one dose of HPV vaccine.
‡All n’s may not equal 300 or 99 due to missing data.
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Table 4
Multivariate Logistic Regression for Factors Associating with HPV Vaccination Initiation†
Variable OR 95% CI* p
Health Status
 Cancer Survivor 1.00
 Healthy Control 1.14 0.43 to 2.98 .796
Daughter’s Age
 Preadolescents, 9–13 years 1.00
 Adolescents, 14–17 years 5.82 2.00 to 16.91 .001
Doctor Recommended Vaccine
 No 1.00
 Yes 6.54 2.56 to 16.73 .000
Health Belief Factor: Vulnerability
 Low 1.00
 High 0.45 0.19 to 1.04 .062
Health Belief Factor: Barriers
 Low 1.00
 High 0.26 0.10 to 0.70 .008
*CI = confidence interval for odds ratio (OR)
†Only variables that were significant or marginally significant predictors in the multivariate analyses are included in this table, with the exception 
of the cancer/no cancer groups.
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Table 5
Multivariate Logistic Regression for Factors Associating with HPV Vaccine Completion†
Variable OR 95% CI* p
Health Status
 Cancer Survivor 1.00
 Healthy Control 1.13 0.36 to 3.58 .839
Race of Maternal Caregiver
 White 1.00
 Non-White 0.26 0.07 to 0.89 .032
Daughter’s Age
 Preadolescents, 9–13 years 1.00
 Adolescents, 14–17 years 4.83 0.93 to 25.05 .061
Health Belief Factor: Vulnerability
 Low 1.00
 High 0.27 0.07 to 1.11 .069
Health Belief Factor: Severity
 Low 1.00
 High 0.17 0.05 to 0.61 .007
Health Belief Factor: Barriers
 Low 1.00
 High 0.21 0.06 to 0.74 .015
*CI = confidence interval for odds ratio (OR)
†Only variables that were significant or marginally significant predictors in the multivariate analyses are included in this table, with the exception 
of the cancer/no cancer groups.
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